Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Managing relapse after CAR-T therapy in ALL

Sara Ghorashian • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia CAR-T

Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, shares some insights into the management of relapse after CAR-T therapy in patients with acute lymphoblastic leukemia (ALL). Dr Ghorashian emphasizes the importance of thorough and systematic data collection and how this data can be used to improve approaches after relapse. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Novartis, UCLB

More from Sara Ghorashian

1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
2:27
The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals